Viracta Subsidiary, Inc.
Precision oncology therapeutics targeting viral-associated cancers
- Sector
- Biotech
- Headquarters
- Cardiff, CA
- Founded
- 2007
- Latest Form D
- $65M, Mar 2021
- Total capital
- $155M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $155M
- 9 Form D · last Mar 2021
- 68 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 3
- 19 pending · first 2023
- Rank in peer group#339 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 9th filing$65M
- Private capital raisedForm D · SEC · 8th filing$40M
- Private capital raisedForm D · SEC · 7th filing$16.8M
- Private capital raisedForm D · SEC · 6th filing$5.7M
- Private capital raisedForm D · SEC · 5th filing$2M
- Private capital raisedForm D · SEC · 4th filing$2.7M
- Private capital raisedForm D · SEC · 3rd filing$9.9M
- Private capital raisedForm D · SEC · 2nd filing$6.5M
- Private capital raisedForm D · SEC · 1st filing$6M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#339 · top 23%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Daniel ChevallardExecutive OfficerNamed in SEC Form D filings
- Gur RoshwalbDirectorNamed in SEC Form D filings
- Ivor RoystonExecutive Officer, DirectorNamed in SEC Form D filings
- Michael HuangDirectorNamed in SEC Form D filings
- Richard GhalieDirectorNamed in SEC Form D filings
- Roger PomerantzDirectorNamed in SEC Form D filings
Show all 7 people
- Samuel MurphyDirectorNamed in SEC Form D filings
What it has protected
USPTO · 3 granted of 22- PendingHistone Deacetylase Inhibitors For Use In ImmunotherapyUSPTOApplication 19320907
- PendingCancer Treatment CombinationsUSPTOApplication 18580500
- GrantedHdac Inhibitor Solid State FormsUSPTOUS 12,012,396
Show all 22 patent records
- Histone Deacetylase Inhibitors For Use In ImmunotherapyJan 1, 2026 · Application 19320907Pending
- Cancer Treatment CombinationsNov 7, 2024 · Application 18580500Pending
- Hdac Inhibitor Solid State FormsJun 18, 2024 · US 12,012,396Granted
- Hdac Inhibitor Solid State FormsMar 28, 2024 · Application 18240853Pending
- Hdac Inhibitor Solid State FormsNov 30, 2023 · Application 18034296Pending
- Hdac Inhibitor Solid State FormsOct 10, 2023 · US 11,780,822Granted
- Hdac Inhibitor Solid State FormsSep 19, 2023 · US 11,760,748Granted
- Histone Deacetylase Inhibitors For Use In ImmunotherapyMay 18, 2023 · Application 18057161Pending
- Hdac Inhibitor Solid State FormsJan 26, 2023 · Application 17830881Pending
- Methods Of Treating Virally Associated Cancers With Histone Deacetylase InhibitorsJul 21, 2022 · Application 17613718Pending
- Epigenetic Modifiers For Use In Cellular ImmunotherapyNov 26, 2020 · Application 16961200Pending
- Dosing Methods For Hdac Inhibitor CompoundsApplication PCTUS2023077256Pending
- Dosing Methods For Hdac Inhibitor CompoundsApplication 63380496Pending
- Cancer Treatment CombinationsApplication PCTUS2022037755Pending
- Methods Of Treating Autoimmune Disorders With Histone Deacetylase InhibitorsApplication 63351629Pending
- Hdac Inhibitor Solid State FormsApplication PCTUS2021057106Pending
- Hdac Inhibitor Solid State FormsApplication PCTUS2020063387Pending
- Dosages For Hdac Treatment With Reduced Side EffectsApplication PCTUS2020054356Pending
- Dosing Methods For Hdac Inhibitor CompoundsApplication 63501647Pending
- Methods Of Treating Virally Associated Cancers With Histone Deacetylase InhibitorsApplication PCTUS2020034951Pending
- Methods Of Treating Autoimmune Disorders With Histone Deacetylase InhibitorsApplication PCTUS2023068289Pending
- Dosing Methods For Hdac Inhibitor CompoundsApplication 63587954Pending
Related companies, and why
- Invenra Inc.Similar federal contract value in Biotech · null in contracts
- LEUKOGENE THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
- CERTICHEM, INC.Similar federal contract value in Biotech · null in contracts
- ReproNovoSimilar federal contract value in Biotech · null in contracts
- Glycologix, LLCSimilar federal contract value in Biotech · null in contracts
- Tremeau Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .